Ekso Bionics (EKSO) Reports Q2 Loss, Lags Revenue Estimates

Another stock from the same industry, Accelerate Diagnostics (AXDX) , has yet to report results for the quarter ended June 2024. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Ekso Bionics (EKSO) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of$0.11. This compares to loss of $0.31 per share a year ago. These figures are adjusted for non-recurring items. Ekso Bionics, which belongs to the Zacks Medical - Instruments ...